Diversify Wealth Management LLC Acquires 4,933 Shares of Repligen Corporation $RGEN

Diversify Wealth Management LLC boosted its holdings in Repligen Corporation (NASDAQ:RGEN) by 56.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 13,616 shares of the biotechnology company’s stock after purchasing an additional 4,933 shares during the period. Diversify Wealth Management LLC’s holdings in Repligen were worth $1,540,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. United Capital Financial Advisors LLC purchased a new stake in shares of Repligen during the 3rd quarter valued at $368,387,000. Opti Capital Management LP bought a new position in Repligen during the fourth quarter valued at about $2,399,209,000. Wasatch Advisors LP bought a new position in Repligen during the first quarter valued at about $146,513,000. Massachusetts Financial Services Co. MA purchased a new stake in Repligen during the fourth quarter worth about $199,176,000. Finally, Price T Rowe Associates Inc. MD increased its holdings in Repligen by 31.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,599,061 shares of the biotechnology company’s stock worth $753,603,000 after buying an additional 1,091,683 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Repligen Price Performance

Repligen stock opened at $147.13 on Wednesday. Repligen Corporation has a 52 week low of $100.99 and a 52 week high of $175.77. The business has a 50-day simple moving average of $127.32 and a 200 day simple moving average of $133.67. The company has a quick ratio of 7.78, a current ratio of 9.20 and a debt-to-equity ratio of 0.26. The stock has a market cap of $8.30 billion, a price-to-earnings ratio of 163.48, a PEG ratio of 2.79 and a beta of 1.06.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.10. Repligen had a return on equity of 4.88% and a net margin of 6.73%.The business had revenue of $194.25 million for the quarter, compared to analyst estimates of $192.05 million. During the same period in the prior year, the company earned $0.39 EPS. The company’s quarterly revenue was up 14.8% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. On average, research analysts forecast that Repligen Corporation will post 1.99 earnings per share for the current fiscal year.

Insider Activity at Repligen

In related news, CFO Jason K. Garland sold 733 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $145.00, for a total value of $106,285.00. Following the sale, the chief financial officer directly owned 19,359 shares of the company’s stock, valued at $2,807,055. This trade represents a 3.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 0.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on RGEN. Benchmark upgraded Repligen from a “hold” rating to a “buy” rating and set a $185.00 price objective on the stock in a research note on Tuesday, July 7th. Royal Bank Of Canada began coverage on Repligen in a research note on Thursday, May 14th. They issued an “outperform” rating and a $160.00 target price for the company. JPMorgan Chase & Co. decreased their price target on Repligen from $180.00 to $165.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 6th. HC Wainwright increased their price target on shares of Repligen from $180.00 to $208.00 and gave the stock a “buy” rating in a report on Monday, March 23rd. Finally, Rothschild & Co Redburn set a $160.00 price objective on shares of Repligen and gave the company a “buy” rating in a research report on Friday, April 17th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $165.00.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.